A Novel Approach in Endoscopic Prostate Surgery: The Rezum System

Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001423. doi: 10.1002/14651858.CD001423.pub2. Update in: Cochrane Database Syst Rev. 2012;12:CD001423.

Zhang SJ, Qian HN, Zhao Y, et al. Relationship between age and prostate size. Asian J Androl. 2013;15:116–120.

Bushman W: Etiology, epidemiology and natural history of BPH. Urol Clin North Am. 2009;36:403-415.

Vuichoud C and Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(1):1–6.

McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association Guideline: Management of benign prostatic hyperplasia (BPH). Linthicum, MD: American Urological Association Education and Research, Inc., http:// www.auanet.org/guidelines

Magistro G, Chapple C, Elhilali M, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017;72: 986–997.

Gravas S, Bach T, Bachmann A, et al. EAU Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO), http://uroweb.org/wp-content/uploads/EAU-GuidelinesManagement-of-non-neurogenic-maleLUTS-2016.pdf

Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, McVary KT: Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202:592-8.

Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ, Somani BK. Medium-term outcomes of urolift (minimum 12 months follow-up): evidence from a systematic review. Urology. 2016;97:20-4.

Darson MF, Alexander EE, Schiffman ZJ, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159-168.

Woo HH, Gonzalez RR. Perspective on the Rezūm® System: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Devices (Auckl). 2017;10:71-80.

McVary KT, Rogers T, Roehrborn CG. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology. 2019;126:171-179.

Mynderse L, Hanson D, Robb R, et al. Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. 2015;86:122–127.

Dixon C, Cedano ER, Pacik D, et al. Two-year results after convective radiofrequency water vapour thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016;8:207–216.

Roehrborn CG, Gange SN, Gittelman MC, et al. Convective water vapor energy (WAVE) ablation therapy: durable two-year results and prospective blinded crossover study for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017;197:1507–1516.

Rassweiler J, Teber D, Kuntz R, et al. Complications of transurethral resection of the prostate (TURP): incidence, management, and prevention. Eur Urol. 2006;50:969–979.

Gupta N, Rogers T, Holland B, et al. 3-year treatment outcomes of water vapor thermal therapy (Rezum System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) trial. J Urol. 2018;200(2):405–413.

McVary KT and Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezum system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2018;111: 1–9.

Higazy A, Osman D, Osman T. Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article. Int Urol Nephrol. 2021;53(9):1747-1756.

Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR. Water vapor thermal therapy for obstructive benign prostatic hyperplasia. Can J Urol. 2019;26(1):9787–9793.

McVary K, Gange S, Gittelman M, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195:1529–1538.

Guelce D, Thomas D, Elterman D, Chughtai B. Recent advances in managing benign prostatic hyperplasia: the Rezūm System. F1000 Research. 2018;7(0):1916.

Yalçın S, Tunç L. Indications, techniques, and role of new minimally invasive benign prostate hyperplasia surgical options. Turk J Urol. 2020;46(1):79-91.

Mollengarden D, Goldberg K, Wong D, Roehrborn C. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single ofce experience. Prostate Cancer Prostatic Dis. 2018;21(3):379–385.

Johnston MJ, Noureldin M, Abdelmotagly Y, et al. Rezum water vapour therapy: promising early outcomes from the first UK series. BJU Int. 2020;126(5):557-558.

Bole R, Gopalakrishna A, Kuang R, et al. Comparative Postoperative Outcomes of Rezūm Prostate Ablation in Patients with Large Versus Small Glands. J Endourol. 2020;34(7):778-781.

Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001423. doi: 10.1002/14651858.CD001423.pub2. Update in: Cochrane Database Syst Rev. 2012;12:CD001423.

Zhang SJ, Qian HN, Zhao Y, et al. Relationship between age and prostate size. Asian J Androl. 2013;15:116–120.

Bushman W: Etiology, epidemiology and natural history of BPH. Urol Clin North Am. 2009;36:403-415.

Vuichoud C and Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(1):1–6.

McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association Guideline: Management of benign prostatic hyperplasia (BPH). Linthicum, MD: American Urological Association Education and Research, Inc., http:// www.auanet.org/guidelines

Magistro G, Chapple C, Elhilali M, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017;72: 986–997.

Gravas S, Bach T, Bachmann A, et al. EAU Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO), http://uroweb.org/wp-content/uploads/EAU-GuidelinesManagement-of-non-neurogenic-maleLUTS-2016.pdf

Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, McVary KT: Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202:592-8.

Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ, Somani BK. Medium-term outcomes of urolift (minimum 12 months follow-up): evidence from a systematic review. Urology. 2016;97:20-4.

Darson MF, Alexander EE, Schiffman ZJ, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159-168.

Woo HH, Gonzalez RR. Perspective on the Rezūm® System: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Devices (Auckl). 2017;10:71-80.

McVary KT, Rogers T, Roehrborn CG. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology. 2019;126:171-179.

Mynderse L, Hanson D, Robb R, et al. Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. 2015;86:122–127.

Dixon C, Cedano ER, Pacik D, et al. Two-year results after convective radiofrequency water vapour thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016;8:207–216.

Roehrborn CG, Gange SN, Gittelman MC, et al. Convective water vapor energy (WAVE) ablation therapy: durable two-year results and prospective blinded crossover study for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017;197:1507–1516.

Rassweiler J, Teber D, Kuntz R, et al. Complications of transurethral resection of the prostate (TURP): incidence, management, and prevention. Eur Urol. 2006;50:969–979.

Gupta N, Rogers T, Holland B, et al. 3-year treatment outcomes of water vapor thermal therapy (Rezum System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) trial. J Urol. 2018;200(2):405–413.

McVary KT and Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezum system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2018;111: 1–9.

Higazy A, Osman D, Osman T. Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article. Int Urol Nephrol. 2021;53(9):1747-1756.

Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR. Water vapor thermal therapy for obstructive benign prostatic hyperplasia. Can J Urol. 2019;26(1):9787–9793.

McVary K, Gange S, Gittelman M, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195:1529–1538.

Guelce D, Thomas D, Elterman D, Chughtai B. Recent advances in managing benign prostatic hyperplasia: the Rezūm System. F1000 Research. 2018;7(0):1916.

Yalçın S, Tunç L. Indications, techniques, and role of new minimally invasive benign prostate hyperplasia surgical options. Turk J Urol. 2020;46(1):79-91.

Mollengarden D, Goldberg K, Wong D, Roehrborn C. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single ofce experience. Prostate Cancer Prostatic Dis. 2018;21(3):379–385.

Johnston MJ, Noureldin M, Abdelmotagly Y, et al. Rezum water vapour therapy: promising early outcomes from the first UK series. BJU Int. 2020;126(5):557-558.

Bole R, Gopalakrishna A, Kuang R, et al. Comparative Postoperative Outcomes of Rezūm Prostate Ablation in Patients with Large Versus Small Glands. J Endourol. 2020;34(7):778-781.